SHR‐1316 , an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study-Reference-Cited by-同舟云学术

SHR‐1316 , an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

Published:2021-03-24 Issue: Volume: Page:
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Mu Lan¹,Song Yan¹,Zhao Kuaile²³,Liu Ying⁴,Fan Qingxia⁵,Wang Xi¹,Li Qun¹,Wang Xiaopeng⁶,Huang Jing¹⁷^ORCID

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China

3. Department of Oncology, Shanghai Medical College Fudan University Shanghai China

4. Department of Medical Oncology of Henan Cancer Hospital Zhengzhou University Affiliated Cancer Hospital Zhengzhou China

5. Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

6. Department of Clinical Medicine Jiangsu Hengrui Medicine Co. Ltd Lianyungang China

7. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13913

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global trends in esophageal cancer

3. Epidemiology of Esophageal Squamous Cell Carcinoma

4. Phase II Evaluation of Protracted Infusion of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407)

5. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes;Frontiers in Immunology;2024-07-29

2. Efficacy and safety of PD-1 Monoclonal antibodies in the treatment of esophageal squamous cell carcinoma: Systematic review and meta Regression;Heliyon;2024-07

3. Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics;Future Medicinal Chemistry;2024-07

4. Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer;Biomedicine & Pharmacotherapy;2024-07

5. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial;Nature Medicine;2023-07-24